Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Starts US Phase II Trial of CLDN18.2 CAR-T for Gastric Cancer

publication date: May 19, 2023

Shanghai CARsgen Therapeutics has started enrolling patients in a US Phase II trial of CT041, a CAR-T candidate, in patients with CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ). CT041 is an autologous CLDN18.2 CAR T-cell candidate that, CARsgen believes, could be the first-in-class globally. CARsgen’s lead drug, a BCMA CAR-T-Cell therapy, is currently under NDA review in China for relapsed/refractory multiple myeloma. The company develops CAR-T therapies for hematological and solid tumor cancers in China and the US. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here